Relapse incidence of patients with AML with mutant IDH MRD stratified by NPM1 mutational and FLT3-ITD status at diagnosis. (A) CIR of patients with IDH1-mutated AML with detectable (red) and undetectable (blue) mutant IDH1 MRD among those with a concomitant NPM1 mutation at diagnosis. (B) CIR of patients with IDH2-mutated AML with detectable (red) and undetectable (blue) mutant IDH2 MRD among those with a concomitant NPM1 mutation at diagnosis. (C) CIR of patients with IDH1-mutated AML with detectable (red) and undetectable (blue) mutant IDH1 MRD in those with a concomitant FLT3-ITD at diagnosis. (D) CIR of patients with IDH2-mutated AML with detectable (red) and undetectable (blue) mutant IDH2 MRD among those with a concomitant FLT3-ITD at diagnosis. (E) CIR of patients with IDH1-mutated AML with detectable (red) and undetectable (blue) mutant IDH1 MRD in those without concomitant mutant NPM1 or FLT3-ITD at diagnosis. (F) CIR of patients with IDH2-mutated AML with detectable (red) and undetectable (blue) mutant IDH2 MRD in those without concomitant mutant NPM1 or FLT3-ITD at diagnosis.